Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2001

View Archived Issues

Sepracor makes progress in first quarter of 2001

New HspE7 data confirm earlier findings in anal dysplasia

Positive preclinical and phase I results reported for BioSante's CAP

Lorus Therapeutics provides Q3 update

HIV protease inhibitor from Vertex/GSK commences third pivotal clinical trial

Cyclic amide-containing HNE inhibitors with good water solubility and in vivo potency

Collaborative Novartis/Schering effort yields novel antiangiogenic phthalazine

4-Oxohydroquinolines as selective, broad-spectrum antiherpesvirus agents

GW-2286, an orally active, selective VEGF RTK inhibitor

Novel cell cycle inhibitor Ro-41-4439 inhibits tumor growth in animal model

Abbott presents new antiinfluenza candidate at two April meetings

Potential of LTbetaR-Ig for colitis Rx discussed at Tokyo meeting

Lumigan introduced following mid-March approval by FDA

Cell Therapeutics prepares to advance PG-TXL to phase II

HE-2200 improves immune response to vaccination in preclinical study

LMW glycosaminoglycans show promise for preventing AD-associated neuropathology

PH-10 plus green light shows promise in pilot psoriasis study

Japanese study provides further support for use of DHA as AD prophylactic

Zeffix may represent a major advance for children with chronic HBV, according to EASL presentation

InSite Vision researchers prepare ophthalmic compositions of oxazolidinones

Dual PDE4 and TNF production inhibitors described by Pfizer

Cytostatic agent-integrin receptor antagonist conjugates with tumor-specific activity

Growth hormone secretagogues described by Merck for GH deficiency, osteoporosis

Merck KGaA presents new PDE5 inhibitors and their uses

New Merck compounds may have potential in the treatment of anxiety, convulsions

1,2,3-Thiadiazole COX-2 inhibitors designed at Merck Frosst

Ocular medications from Alcon with improved profile compared to PGF2alpha

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...